bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  

  

  

1

A   human   monoclonal   antibody   targeting   a   conserved   pocket   in   the   SARS-­CoV-­2  

2

receptor-­binding  domain  core  

3

  

4

Juliette   Fedry1=,   Daniel   L.   Hurdiss1,2=,   Chunyan   Wang2=,   Wentao   Li2=,   Gonzalo   Obal3,   Ieva  

5

Drulyte4,  Stuart  C.  Howes1,  Frank  J.M.  van  Kuppeveld2,  Friedrich  Förster1#   and  Berend-­Jan  

6

Bosch2#    

7
8
9
10
11
12
13
14
15

  

16

=  Contributed  equally  to  this  work.  

17

#   Address   correspondence   to   Friedrich   Förster   (f.g.forster@uu.nl)   and   Berend-­Jan   Bosch  

18

(b.j.bosch@uu.nl).  

19

  

20

Abstract  

21

SARS-­CoV-­2  has  caused  a  global  outbreak  of  severe  respiratory  disease  (COVID-­19),  leading  

22

to   an   unprecedented   public   health   crisis.   To   date,   there   has   been   over   thirty-­three   million  

23

diagnosed  infections,  and  over  one  million  deaths.  No  vaccine  or  targeted  therapeutics  are  

24

currently  available.  We  previously  identified  a  human  monoclonal  antibody,  47D11,  capable  

25

of   cross-­neutralising   SARS-­CoV-­2   and   the   related   2002/2003   SARS-­CoV   in   vitro,   and  

26

preventing   SARS-­CoV-­2   induced   pneumonia   in   a   hamster   model.   Here   we   present   the  

27

structural  basis  of  its  neutralization  mechanism.  We  describe  cryo-­EM  structures  of  trimeric  

28

SARS-­CoV  and  SARS-­CoV-­2  spike  ectodomains  in  complex  with  the  47D11  Fab.  These  data  

29

reveal  that  47D11  binds  specifically  to  the  closed  conformation  of  the  receptor  binding  domain,  

30

distal   to   the   ACE2   binding   site.   The   CDRL3   stabilises   the   N343   glycan   in   an   upright  

31

conformation,  exposing  a  conserved  and  mutationally  constrained  hydrophobic  pocket,  into  

32

which   the   CDRH3   loop   inserts   two   aromatic   residues.   Interestingly,   47D11   preferentially  

33

selects  for  the  partially  open  conformation  of  the  SARS-­CoV-­2  spike,  suggesting  that  it  could  

34

be   used   effectively   in   combination   with   other   antibodies   that   target   the   exposed   receptor-­

35

binding  motif.  Taken  together,  these  results  expose  a  cryptic  site  of  vulnerability  on  the  SARS-­

36

CoV-­2  RBD  and  provide  a  structural  roadmap  for  the  development  of  47D11  as  a  prophylactic  

37

or  post-­exposure  therapy  for  COVID-­19.  

38

  

39

  

1

Cryo-­Electron   Microscopy,   Bijvoet   Center   for   Biomolecular   Research,   Department   of   Chemistry,   Faculty   of   Science,   Utrecht  

University,  Padualaan  8,  3584  CH  Utrecht,  The  Netherlands  
2

Virology   Section,   Infectious   Diseases   and   Immunology   Division,   Department   of   Biomolecular   Health   Sciences,   Faculty   of  

Veterinary  Medicine,  Utrecht  University,  3584CL  Utrecht,  The  Netherlands.  
3

Crystal   and   Structural   Chemistry,   Bijvoet   Center   for   Biomolecular   Research,   Department   of   Chemistry,   Faculty   of   Science,  

Utrecht  University,  Padualaan  8,  3584  CH  Utrecht,  The  Netherlands  
4

Materials  and  Structural  Analysis,  Thermo  Fisher  Scientific,  Eindhoven,  5651  GG,  The  Netherlands.  

  

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  

  

  

40

  

41

Introduction  

42

The   severe   acute   respiratory   syndrome   coronavirus   2   (SARS-­CoV-­2)   emerged   from   a  

43

zoonotic  event  in  China,  late  2019(1).  To  date,  the  resulting  coronavirus  induced  disease  19  

44

(COVID-­19)  pandemic  has  been  responsible  for  over  33  million  infections  and  over  a  million  

45

deaths,   as   of   September   29,   2020(https://covid19.who.int/).   SARS-­CoV-­2   and   SARS-­CoV,  

46

another   highly   lethal   respiratory   pathogen   which   emerged   in   2002/2003(2),   belong   to   the  

47

Sarbecovirus   subgenus   (genus   Betacoronavirus,   family   Coronaviridae)(3).   At   present,   no  

48

targeted  therapeutics  have  been  approved  for  COVID-­19,  meaning  there  is  an  urgent  clinical  

49

need  for  potent  antiviral  therapies  to  halt  the  spread  of  SARS-­CoV-­2  and  to  pre-­empt  future  

50

outbreaks   caused   by   SARS-­like   viruses.   Antibodies   are   a   promising   class   of   drugs   for  

51

combatting  infectious  diseases  and  have  shown  therapeutic  efficacy  for  a  number  of  viruses(4,  

52

5),   including   in   the   treatment   of   SARS   and   COVID-­19(6,   7).   Such   antibodies   function   by  

53

targeting  vulnerable  sites  on  viral  surface  proteins.  

54

  

55

The   coronavirus   trimeric   spike   (S)   glycoprotein,   located   on   the   viral   envelope,   is   the   key  

56

mediator   of   viral   entry   into   host   cells.   The   spike   protein   consists   of   two   main   parts:   S1   is  

57

involved  in  receptor  binding  and  S2  is  the  membrane  fusion  domain.  The  S1  domain  itself  is  

58

further  subdivided  into  an  N-­terminal  domain  (NTD,  or  S1A)  and  a  receptor  binding  domain  

59

(RBD,   or   S1B)(8,   9).   The   spike   proteins   of   SARS-­CoV-­2   (SARS2-­S;;   1273   residues,   strain  

60

Wuhan-­Hu-­1)  and  SARS-­CoV  (SARS-­S,  1255  residues,  strain  Urbani)  exhibit  77.5%  identity  

61

in  their  primary  amino  acid  sequence  and  are  structurally  conserved.  The  spike  trimer  exists  

62

in  equilibrium  between  a  closed  conformation,  where  all  three  RBD  are  lying  flat,  and  a  partially  

63

open   conformation,   where   one   RBD   stands   upright   and   is   exposed   for   receptor  

64

engagement(10-­12).  Both  viruses  use  the  human  angiotensin  converting  enzyme  2  (ACE2)  

65

protein   as   a   host   receptor,   with   binding   mediated   through   interactions   with   the   receptor-­

66

binding  motif  (RBM)  located  on  the  RBD,  and  the  N-­terminal  helix  of  ACE2(13).  The  spike-­

67

mediated  fusion  of  viral  and  cellular  membranes  is  tightly  regulated  and  triggered  by  a  cascade  

68

of  preceding  events.  The  first  step  involves  the  attachment  of  SARS-­CoV-­2  to  the  target  cell  

69

surface  via  the  interaction  between  spike  and  ACE2(13,  14).  In  the  second  step,  the  spike  

70

protein   needs   to   be   primed   for   membrane   fusion   by   host   proteases   (e.g.   cellular  

71

transmembrane   serine   protease   2)   which   cleave   the   spike   at   multiple   sites(15),   enabling  

72

shedding   of   S1.   Finally,   the   free   S2   catalyses   the   fusion   of   the   viral   and   the   host  

73

membranes(16,  17),  causing  the  release  of  the  viral  genome  into  the  host  cell  cytoplasm.  

74

  

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  

  

  

75

The  S  glycoprotein  is  the  primary  target  for  neutralising  antibodies,  making  it  the  main  target  

76

for  vaccine  development(18).  Indeed,  a  number  of  SARS-­CoV-­2  neutralising  antibodies  have  

77

now  been  described(19-­33).  However,  comparatively  few  cross-­neutralising  antibodies  have  

78

been  reported(20,  25,  30,  34),  of  which  only  a  handful  have  been  structurally  characterised(29,  

79

35-­37).  The  most  commonly  identified  antibodies  neutralize  coronaviruses  by  binding  to  the  

80

receptor   interaction   site   in   S1,   blocking   receptor   interactions   and/or   promoting   premature  

81

conformational   change   of   spike   to   the   post-­fusion   state.   However,   a   smaller   number   of  

82

antibodies  have  been  reported  to  bind  sites  which  are  distal  to  the  ACE2  binding  site.  Such  

83

antibodies   target   the   RBD-­core(27,   35,   37,   38),   or   even   the   NTD(39).   Several   promising  

84

vaccines  are  currently  being  developed  but  it  is  estimated  that  at  least  a  year  will  be  needed  

85

before  they  can  be  introduced  on  the  market.  Hence  there  is  an  urgent  need  for  characterized  

86

antibodies  to  form  cocktails  for  the  treatment  by  passive  immunization  of  COVID-­19  patients.  

87

Combined  structural  and  functional  studies  are  thus  required  to  determine  the  epitopes  and  

88

investigate   the   molecular   mechanisms   of   SARS-­CoV-­2   neutralizing   antibodies.   Moreover,  

89

such  studies  may  identify  cryptic  sites  of  vulnerability  which  can  guide  vaccine  and  antiviral  

90

development(40).  

91

  

92

We   recently   reported   the   first   human   monoclonal   antibody,   47D11,   capable   of   cross-­

93

neutralising   SARS-­CoV   and   SARS-­CoV-­2   at   1.3   and   3.8   nM,   respectively(41),   Moreover,  

94

recent  pre-­clinical  studies  show  that  47D11  protects  against  lower  respiratory  tract  disease  in  

95

a   hamster   model(42).   However,   its   mode   of   engagement   with   the   spike   protein   remained  

96

unclear.  We  thus  employed  structural  and  functional  studies  to  decipher  the  molecular  basis  

97

for  47D11-­mediated  neutralisation.  

98

  

99

Results  

100

47D11  specifically  binds  to  the  closed  receptor  binding  domain  

101

To  understand  how  47D11  binds  to  the  SARS-­CoV  and  SARS-­CoV-­2  spike  proteins,  we  used  

102

cryo-­electron   microscopy   (cryo-­EM)   to   determine   structures   of   prefusion   stabilised  

103

ectodomain   trimers   in   complex   with   the   47D11   Fab   fragment.   The   resulting   cryo-­EM   maps  

104

have  global  resolutions  of  3.8  Å  and  4.0  Å  resolution  for  SARS-­S  and  SARS2-­S,  respectively  

105

(Supplementary  Figure1A-­F).  For  previously  reported  apo  S  trimers,  both  the  open  and  closed  

106

conformation   are  observed,   with   the   latter  being  predominant   (56%   for   SARS   and   67%   for  

107

SARS2(11,  43)).  Upon  incubation  with  47D11,  only  the  closed  conformation  of  the  SARS  spike  

108

was  observed,  with  stochiometric  binding  of  47D11  to  each  RBD  (Figure  1A).  Interestingly,  for  

109

SARS-­CoV-­2,  only  the  partially  open  conformation  of  spike  was  observed,  with  one  Fab  bound  

110

to   each   of   the   closed   RBDs,   and   the   remaining   open   RBD   unoccupied   and,   in   principle,  

111

accessible  to  ACE2  binding  (Figure  1B).  The  sub  stochiometric  binding  observed  for  SARS2-­

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  

  

  

112

S  may  partially  explain  our  previous  observations  that  47D11  binds  to  the  SARS-­S  with  higher  

113

affinity   than   SARS2-­S   (equilibrium   dissociation   constant   [KD]   of   0.745   nM   and   10.8   nM,  

114

respectively)(41).  To  understand  why  47D11  favours  different  spike  conformations  for  SARS-­

115

CoV   and   SARS-­CoV-­2,   we   first   superposed   the   Fab-­bound   structures   with   their   apo  

116

counterparts.   Compared   to   the   apo   partially   open   SARS2-­S   structure,   the   RBDs   are   less  

117

compact  when  47D11  is  bound  (Figure  2A).  The  apo  conformation  of  the  closed  RBD  would  

118

preclude   binding   of  47D11   through   steric  hindrance.   To   accommodate   the   bound   Fab,   this  

119

RBD  shifts  outwards  by  ~7  Å  (Figure  2B).  Unlike  S309  and  H014(35,  38),  two  other  RBD-­core  

120

targeting  SARS  neutralizing  antibodies,  there  was  no  indication  from  our  cryo-­EM  data  that  

121

47D11   can   bind   to   the   open   conformation   of   the   SARS2-­S   RBD.   In   line   with   this,  

122

superimposition  of  open  and  closed  SARS2-­S  RBDs  revealed  that  47D11  would  clash  with  

123

the  adjacent  N-­terminal  domain  (NTD)  and  the  N331  glycan  in  the  latter  conformation  (Figure  

124

2C).  Similar  to  SARS2-­S,  the  RBDs  of  the  47D11  bound  SARS-­S  are  also  less  compact  than  

125

the  reported  apo  fully  closed  structure  (Figure  2D).  However,  in  contrast  to  SARS2-­S,  there  is  

126

a  potential  stabilising  salt  bridge  between  D463,  located  on  the  receptor  binding  ridge  (RBR),  

127

and  R18  on  the  47D11  light  chain  (Figure  2E).  Indeed,  the  RBR  exhibits  the  most  prominent  

128

structural  differences  between  SARS2-­S  and  SARS-­S(13).  This  epitope  distal  loop,  located  

129

within  the  ACE2-­binding  region,  contains  an  essential  disulfide  bridge  in  both  viruses,  but  is  

130

more  compact  in  SARS-­S.  In  order  to  test  whether  the  epitope  distal  RBR  impacts  binding  of  

131

47D11   to   the   SARS-­S   and   SARS2-­S,   we   swapped   loop   residues   470-­490   (SARS2-­S  

132

numbering)  and  produced  chimeric  ectodomains.  In  support  of  our  hypothesis,  the  SARS2-­S,  

133

containing  the  SARS-­S  RBR  loop,  exhibited  increased  binding  to  47D11.  However,  we  did  not  

134

observe   an   equivalent   loss   of   binding   for   the   chimeric   SARS-­S,   suggesting   that   other  

135

differences  in  protein  sequence  or  quaternary  structure  may  be  involved  (Figure  2F).  Taken  

136

together,  our  data  shows  that  47D11  binding  to  the  closed  RBDs  of  the  trimeric  spike  protein  

137

has  differing  outcomes  for  SARS-­S  and  SARS2-­S,  trapping  them  in  the  fully  closed  and  the  

138

partially  open  conformation,  respectively  (Figure  S2).  

139

  

140

47D11  targets  a  conserved  hydrophobic  pocket  in  the  RBD  

141

The   47D11   epitope   is   distinct   from   the   ACE2   binding   site   (Figure   3A),   consistent   with   our  

142

recently  reported  functional  data(41).  The  protein/glycan  epitope  is  located  on  the  core  domain  

143

of   the  SARS-­S   and  SARS2-­S   RBD.   As  expected,   the   mode  of   binding   is  highly   similar   for  

144

SARS-­S   and   SARS2-­S   (Figure   S3A),   with   the   aligned   47D11:RBD   complexes   having   an  

145

RMSD  value  of  1.4  Å.  The  paratope  is  composed  of  CDRL3  and  CDRH3  loops,  that  form  a  

146

primarily  hydrophobic  interaction  with  the  RBD  surface  of  ~830  Å2  and  ~800  Å2  for  SARS-­S  

147

and  SARS2-­S,  respectively.  The  side  chain  of  47D11  CDRL3  tryptophan  W94  stacks  against  

148

the   N330/N343   (SARS/SARS2)   glycan   tree,   contributing   to   its   stabilization   in   an   upright  

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  

  

  

149

conformation   (Figure   3B).   This   reveals   a   hydrophobic   pocket   into   which   the   CDRH3   loop  

150

projects,   allowing   Fab   residues   W102   and   F103   to   interact   with   RBD   core   residues   F338,  

151

F342,  Y365,  V367,  L368,  F374  and  W436  (F325,  F329,  Y352,  V354,  L355,  F361  and  W423  

152

in  SARS-­S)  –  figure  3B  and  S3B.  Interestingly,  this  pocket  is  normally  shielded  by  the  N343  

153

glycan   in   previously   reported   SARS2-­S   structures   (Figure   3C-­D)(11,   12).   In   order   to  

154

accommodate   the   CDRH3   loop   residues,   the   helix   encompassing   residues   365-­370   is  

155

displaced  outwards  by  2  Å,  creating  55  Å3  of  solvent  accessible  volume  which  is  not  present  

156

in   the   apo   RBD   (Figure   3C-­D   and   Figure   S3C-­D).   Of   note,   the   region   directly   below   this  

157

hydrophobic   pocket   was   recently   shown   bind   to   linoleic   acid,   which   stabilises   the   closed  

158

conformation  of  spike  by  spanning  two  adjacent  RBDs(44).  However,  the  distance  between  

159

the  47D11-­bound  RBDs  is  too  great  to  be  bridged  by  linoleic  acid.  Consistent  with  this,  no  

160

density  consistent  with  linoleic  acid  was  present  in  any  of  our  reconstructions.  

161

  

162

To  verify  the  47D11  epitope,  we  introduced  alanine  mutations  at  each  of  the  identified  contact  

163

residues  in  the  context  of  full-­length  spike  protein.  In  addition,  a  spike  mutant  with  the  naturally  

164

occurring  V367F  minority  variant  was  generated(45).  Binding  of  47D11  to  surface  expressed  

165

wildtype  and  mutant  spike  proteins  was  assessed  by  flow  cytometry.  Soluble  Fc-­tagged  ACE2  

166

and  the  RBD  core  binding  mAb  CR3022  were  taken  along  as  controls.  The  V367F  substitution  

167

and  the  alanine  substitute  at  this  position  only  had  a  minor  effect  on  47D11  antibody  binding  

168

(Figure   3E),   consistent   with   data   showing   that   this   polymorphism   had   no   effect   on  

169

neutralisation  of  SARS2-­S  pseudo  type  virus  (Figure  3I).  Collectively,  this  indicates  that  47D11  

170

would   be   effective   against   this   SARS-­CoV-­2   variant.   In   contrast,   all   other   amino   acid  

171

substitutions  in  the  hydrophobic  core  not  only  reduced  cell-­surface  binding  by  47D11  (Figure  

172

3E),  but  also   prevented  binding   of  ACE2   and   the   core   targeting   antibody   CR3022,   despite  

173

being  distal  to  their  respective  interaction  sites  (Figure  3F-­G  and  Figure  S4A-­B).  Total  cellular  

174

expression   of   mutants   was   comparable   to   wildtype   spike   protein   as   demonstrated   by   an  

175

antibody   targeting   the   C-­terminal   appended   Flag-­tag   on   the   spike   proteins   (Figure   3H),  

176

suggesting  that  mutations  in  the  RBD  hydrophobic  core  have  a  detrimental  effect  on  protein  

177

folding,   compromising   the   tertiary   structure   of   the   RBD.   A   recent   study   reported   deep  

178

mutational  scanning  of  SARS2-­S  RBD  residues,  revealing  how  mutation  of  each  of  the  RBD  

179

residues  affects  expression  of   folded  protein   and   its  affinity   for   ACE2(46).   When  the   mean  

180

mutation  effect  on  expression  was  mapped  on  the  47D11  bound  RBD,  we  observed  that  the  

181

hydrophobic   pocket,   targeted   by   47D11,   is   highly   mutationally   constrained   (Figure   3J).  

182

Another  SARS-­CoV  and  SARS-­CoV-­2  neutralising  antibody,  S309,  targets  a  similar  region  to  

183

47D11,  but  here  the  orientation  of  the  N343  glycan  prohibits  access  to  the  hydrophobic  pocket,  

184

similarly  to  apo  structures  (Figure  3K)(35).  The  47D11  epitope  is  distinct  from  other  reported  

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  

  

  

185

RBD-­core   targeting   antibodies/nanobodies,   such   as   CR3022,   H014   and   VHH-­72   (Figure  

186

S4)(27,  38,  47).    

187

  

188

Comparative  sequence  analysis  revealed  that  the  47D11  epitope  is  highly  conserved  across  

189

circulating   SARS-­like   viruses   (Figure   4A   and   S5).   This   is   in   contrast   to   the   ACE2   binding  

190

region  which  exhibits  the  greatest  sequence  variability.  In  order  to  assess  whether  47D11  has  

191

broad  reactivity,  we  recombinantly  expressed  the  RBD  from  WIV16,  HKU3-­3  and  HKU9-­3  and  

192

analysed   47D11   binding   to   these   related   sarbecoviruses.   The   results   demonstrated   that  

193

47D11  can  bind  to  the  WIV16  RBD  with  similar  affinity  to  SARS-­S  and  SARS2-­S  (Figure  4B).  

194

Closer   inspections   of   the   aligned   RBD   amino   acid   sequences   revealed   that   the   N343  

195

glycosylation  site,  as  well  as  the  hydrophobic  pocket,  are  strictly  conserved  between  these  

196

three  SARS-­like  viruses  (Figure  4C).  Therefore,  the  lack  of  binding  observed  for  HKU3-­3  and  

197

HKU9-­3  may  be  due  to  epitope  adjacent  sequence  differences  which  preclude  binding  of  the  

198

CDRH3  loop.  Nevertheless,  the  potent  binding  observed  for  WIV16  underscores  the  potential  

199

of  47D11  as  a  treatment  for  future  outbreaks  caused  by  SARS-­like  viruses.  

200

  

201

In   conclusion,   our   structural   and   functional   analyses   demonstrate   that   47D11   is   able   to  

202

unmask   a   conserved   and   mutationally   constrained   epitope   on   the   SARS-­CoV-­2   RBD   by  

203

stabilising  the  N343  glycan  in  an  upright  conformation.  Once  this  site  is  exposed,  the  CDRH3  

204

loop  is  able  to  insert  two  aromatic  residues  into  the  hydrophobic  core  of  the  RBD,  inducing  

205

conformational  changes  which  lead  to  the  formation  of  a  55  Å3  cavity.  This  cryptic  site  offers  

206

an  attractive  target  for  design  of  vaccines  and  targeted  therapeutics.  The  47D11  epitope  is  

207

distal  to  the  ACE2  receptor  binding  motif,  rationalising  its  ability  to  cross-­neutralize  SARS-­CoV  

208

and   SARS-­CoV-­2   independently   of   receptor-­binding   inhibition.   Our   structural   analysis   also  

209

shows  that  47D11  exhibits  differing  conformational  selectivity  for  the  SARS-­S  and  SARS2-­S,  

210

providing  a  possible  explanation  for  the  differences  in  observed  binding  affinity.  Two  recently  

211

described   SARS-­CoV-­2   specific   mAbs,   C144   and   S2M11,   recognise   quaternary   epitopes  

212

which   partially   overlap   with   47D11,   and   lock   the   SARS-­CoV-­2   spike   in   the   fully   closed  

213

conformation(48,   49).   In   contrast,   47D11   selects   for   the   partially   open   conformation   of   the  

214

SARS-­CoV-­2  spike  protein,  suggesting  that  it  may  render  the  spike  more  susceptible  to  other  

215

monoclonal   antibodies   which   target   the   exposed   receptor-­binding   subdomain,   making   it   a  

216

prime  candidate  for  combination  treatment.  Antibody  combinations  targeting  non-­overlapping  

217

epitopes  may  act  synergistically  permitting  a  lower  dosage  and  an  increased  barrier  to  immune  

218

escape(49).  Genetic  diversity  for  SARS2  is  currently  limited,  as  the  virus  has  gone  through  a  

219

genetic   bottleneck   during   the   singular   animal-­to-­human   spill-­over   event.   However,   the  

220

genetic/antigenic   variation   will   increase   in   time,   as   observed   for   the   endemic   human  

221

coronavirus   HCoV-­229E,   which   exhibits   cumulative   sequence   variation   in   the   RBD   loops  

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  

  

  

222

which  engage  its  cellular  receptor(50).  The  seemingly  limited  mutational  space  of  the  47D11  

223

epitope,  in  addition  to  its  cross-­reactivity  within  the  Sarbecovirus  subgenus,  may  confer  the  

224

antibody   sustainable   applicability   in   neutralizing   a   wide   range   of   future-­emerging   virus  

225

variants.    

226

  

227

Methods  

228

Expression  and  purification  of  coronavirus  spike  proteins  

229

To   express   the   prefusion   spike   ectodomain,   gene   encoding   residues   1−1200   of   SARS2   S  

230

(GenBank:   QHD43416.1)   with   proline   substitutions   at   residues   986   and   987,   a   “AAARS”  

231

substitution  at   the  furin   cleavage   site   (residues  682–685)   and   residues  1-­1160   of   SARS   S  

232

(GenBank:  AAP13567.1)  with  proline  substitutions  at  residues  956  and  957,  a  C-­terminal  T4  

233

fibritin   trimerization   motif,   a   StrepTag   was   synthesized   and   cloned   into   the   mammalian  

234

expression   vector   pCAGGS.   Similarly,   pCAGGS   expression   vectors   encoding   S1   or   its  

235

subdomain   S1B   of   SARS   (S1,   residues   1-­676;;   S1B,   residues,   325-­533),   and   SARS2   (S1,  

236

residues   1-­682;;   S1B,   residues   333-­527)   C-­terminally   tagged   with   Fc   domain   of   human   or  

237

mouse  IgG  or  Strep-­tag  were  generated  as  described  before(41).  Recombinant  proteins  and  

238

antibody   47D11   were   expressed   transiently   in   FreeStyle™   293-­F   Cells   (Thermo   Fisher  

239

Scientific)  and  affinity  purified  from  the  culture  supernatant  by  protein-­A  sepharose  beads  (GE  

240

Healthcare)   or   streptactin   beads   (IBA)   purification.   Purity   and   integrity   of   all   purified  

241

recombinant  proteins  was  checked  by  coomassie  stained  SDS-­PAGE.  

242

  

243

Pseudotyped  virus  neutralization  assay  

244

Neutralization   with   SARS2-­S   VSV   pseudotyped   viruses   was   performed   as   described  

245

previously  (41).  HEK-­293T  cells  were  transfected  with  pCAGGS  expression  vectors  encoding  

246

SARS2-­S   carrying   a   18-­a.a.   cytoplasmic   tail   truncation,   respectively.   One   day   post  

247

transfection,  cells  were  infected  with  the  VSV-­G  pseudotyped  VSVΔG  expressing  the  firefly  

248

(Photinus  pyralis)  luciferase.  Twenty-­four  hours  later,  cell  supernatants  containing  SARS2-­S  

249

pseudotyped   VSV   particles   were   harvested   and   titrated   on   African   green   monkey   kidney  

250

VeroE6   (ATCC#CRL-­1586)   cells.   In   the   virus   neutralization   assay,   mAbs   were   threefold  

251

serially  diluted  and  mixed  with  an  equal  volume  of  pseudotyped  VSV  particles  and  incubated  

252

for   1  hour   at   room   temperature   (RT).   The   virus/antibody   mix   was   subsequently   added   to  

253

confluent  VeroE6  monolayers  in  96-­well  plate,  and  incubated  at  37°C.  After  24  hours,  cells  

254

were  washed  and  lysis  buffer  (Promega)  was  added.  Luciferase  activity  was  measured  on  a  

255

Berthold  Centro  LB  960  plate  luminometer  using  D-­luciferin  as  a  substrate  (Promega).  The  

256

percentage  of  infectivity  was  calculated  as  ratio  of  luciferase  readout  in  the  presence  of  mAbs  

257

normalized   to   luciferase   readout   in   the   absence   of   mAb.   The   half   maximal   inhibitory  

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  

  

  

258

concentration  (IC50)  was  determined  using  4-­parameter  logistic  regression  (GraphPad  Prism  

259

version  8).  

260

  

261

ELISA  analysis  of  antibody  binding  to  CoV  spike  antigens  

262

ELISA  was  performed  as  described  previously  (41).  Briefly,  NUNC  Maxisorp  plates  (Thermo  

263

Scientific)   coated   with   equimolar   antigen   amounts   were   blocked   with   3%   bovine   serum  

264

albumin  (Bio-­Connect)  in  PBS  containing  0.1%  Tween-­20  at  RT  for  2  hours.  Fourfold  serial  

265

dilutions  of  mAbs  starting  at  10  µg/ml  (diluted  in  blocking  buffer)  were  added  and  plates  were  

266

incubated  for  1  hour  at  RT.  Plates  were  washed  three  times  and  incubated  with  horseradish  

267

peroxidase   (HRP)-­conjugated  goat   anti-­human   secondary   antibody   (ITK   Southern   Biotech)  

268

diluted  1:2000  in  blocking  buffer  for  1  hour  at  RT.  An  HRP-­conjugated  anti-­StrepMAb  (IBA)  

269

antibody  was  used  to  corroborate  equimolar  coating  of  the  Strep-­tagged  spike  antigens.  HRP  

270

activity  was  measured  at  450  nanometer  using  tetramethylbenzidine  substrate  (BioFX)  using  

271

an  ELISA  plate  reader  (EL-­808,  Biotek).  Half-­maximum  effective  concentration  (EC50)  binding  

272

values   were   calculated   by   non-­linear   regression   analysis   on   the   binding   curves   using  

273

GraphPad  Prism  (version  8).  

274

  

275

Preparation  of  Fab-­47D11  from  IgG  

276

47D11  Fab  was  digested  from  IgG  with  papain  using  a  Pierce  Fab  Preparation  Kit  (Thermo  

277

Fisher  Scientific),  following  the  manufacturer’s  standard  protocol.  

278

  

279

Cryo-­EM  sample  preparation  and  data  collection  

280

3  μL  of  SARS2-­S  or  SARS-­S  at  1.6  mg/mL  was  mixed  with  0.85  μL  of  Fab  47D11  at  4  mg/mL  

281

and  incubated  for  50  s  at  RT.  The  sample  was  applied  onto  a  freshly  glow  discharged  R1.2/1.3  

282

Quantifoil   grid   in   a   Vitrobot   Mark   IV   (Thermo   Fisher  Scientific)   chamber  pre-­equilibrated  at  

283

4°C  and  100%  humidity.  The  grid  was  immediately  blotted  at  force  0  for  5  s  and  plunged  into  

284

liquid   ethane.   Data   was   acquired   on   a   200   kV   Talos   Arctica   (Thermo   Fisher   Scientific)  

285

equipped  with  a  Gatan  K2  Summit  direct  detector  and  Gatan  Quantum  energy  filter  operated  

286

in  zero-­loss  mode  with  a  20  eV  slit  width.  To  account  for  the  preferred  orientation  exhibited  by  

287

the  spike  ectodomains,  automated  data  collection  at  tilts  0°,  20°,  and  30°  was  carried  out  using  

288

EPU  2  software  (Thermo  Fisher  Scientific),  and  data  at  tilt  40°  using  SerialEM(51).  A  nominal  

289

magnification  of  130,000x,  corresponding  to  an  effective  pixel  size  of  1.08  Å,  was  used.  Movies  

290

were  acquired  in  counting  mode  with  a  total  dose  of  40e/Å2  distributed  over  50  frames.  4,231  

291

movies   were   acquired   for   SARS2   and   3,247   movies   for   SARS-­S,   with   defocus   ranging  

292

between  0.5  μm  and  3  μm.    

293

  

294

  

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  

  

  

295

Cryo-­EM  data  processing  

296

Single-­particle  analysis  was  performed  in  Relion  version  3.1.(52).  The  data  was  processed  in  

297

four  separate  batches,  corresponding  to  the  stage  tilt  angle  used  for  the  acquisition.  Drift  and  

298

gain  correction  were  performed  with  MotionCor2(53),  CTF  parameters  were  estimated  using  

299

CTFFind4(54)  and  particles  were  picked  using  the  Laplacian  picker  in  Relion(52).  One  round  

300

of   2D   classification   was   performed   on   each   batch   of   data   and   particles   belonging   to   well  

301

defined  classes  were  retained.  Subsequently,  3D  classification  was  performed,  using  a  50  Å  

302

low-­pass   filtered   partially   open   conformation   as  an   initial   model   (EMD-­21457,(12)),   without  

303

imposing  symmetry.  All  particles  belonging  to  Fab  bound  class  were  then  selected  for  3D  auto-­

304

refinement.   Before   merging   the   different   batches,   iterative   rounds   of   per   particle   CTF  

305

refinement,  3D  auto-­refinement  and  post-­processing  were  used  to  account  for  the  stage  tilt  

306

used  during  data  collection.  The  refined  particle  star  files  from  each  batch  were  then  combined  

307

and  subjected  to  a  final  round  of  3D  auto  refinement,  per  particle  defocus  estimation,  3D  auto-­

308

refinement  and  post  processing,  both  with  and  without  imposed  C3  symmetry.  Overviews  of  

309

the  single-­particle  image  processing  pipelines  are  shown  in  supplementary  figure  6  and  7.  

310

  

311

Model  building  and  refinement  

312

UCSF  Chimera  (version  1.12.0)  and  Coot  (version,  1.0.)  were  used  for  model  building  and  

313

analysis(55,  56).  The  SARS2-­S  model,  in  the  partially  open  conformation  (one  RBD  up,  pdb  

314

6VYB)(12),  was  used  for  the  spike  and  fitted  into  our  density  using  the  UCSF  Chimera  ‘Fit  in  

315

map’  tool(55).  For  SARS  a  closed  protomer  of  the  pdb  6NB6  was  used  as  starting  model(57).  

316

To  build  a  model  for  the  Fab  the  sequence  of  the  variable  regions  of  the  HC  and  the  LC  were  

317

separately  blasted  against  the  pdb.  For  the  HC  variable  region,  the  corresponding  region  of  

318

the  pdb   6IEB   (human   monoclonal  antibody   R15  against   RVFV   Gn)   was  used(58).   The   LC  

319

variable   region   was   modelled  using  the  pdb   6FG1  as  template   (Fab   Natalizumab)(59).   For  

320

both  chains,  the  query  sequence  of  47D11  was  aligned  to  the  template  sequence.  Sequence  

321

identity  was  particularly  high  (87%  and  97%  for  the  HC  and  LC,  respectively).  Phenix  sculptor  

322

was  used  to  create  an  initial  model  for  the  Fab  chains(60),  removing  the  non-­aligning  regions  

323

(notably  the  CDRH3).  This  model  was  fitted  into  our  density  and  the  missing  regions  were  built  

324

manually  in  the  density  map  using  Coot(56).  Models  were  refined  against  the  respective  EM  

325

density   maps   using  Phenix   Real   Space   Refinement  and   Isolde(61)(62),   and   validated   with  

326

MolProbity  and  Privateer  (glycans)(63-­65).  

327

  

328

Analysis  and  visualisation  

329

PDBePISA  was  used  to  identify  spike  residues  interacting  with  47D11(66).  Surface  colouring  

330

of   the   SARS-­CoV-­2   RBD   using   the   Kyte-­Doolittle   hydrophobicity   scale   was   performed   in  

331

UCSF  chimera(55).  Volume  measurements  were  performed  using  CASTp  3.0,  using  a  probe  

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  

  

  

332

radius   of   1.2   Å(67).   In   order   to   colour   the   47D11   bound   RBD   surface   according   to   each  

333

residues   mean   mutational   effect   on   expression,   the   pdb   file   was   populated   with   the   mean  

334

mutation   effect   on   expression   values   described   by   Starr   et   al(46).   The   UCSF   Chimera  

335

‘MatchMaker’   tool   was   used   to   obtain   RMSD   values,   using   default   settings.   Figures   were  

336

generated  using  UCSF  Chimera(55)  and  UCSF  ChimeraX(68).  

337

  

338

Figure  Legends  

339

Figure  1:  47D11  has  differing  conformational  selectivity  for  the  SARS-­CoV  and  SARS-­

340

CoV-­2   spike.   A)   Surface   rendering   of   the   fully   closed   SARS   spike   bound   to   three   47D11  

341

antibody  Fab  fragments,  shown  as  two  orthogonal  views.  (B)  Surface  rendering  of  the  partially  

342

open   SARS2   spike   in   complex   with   two   47D11   antibody   Fab   fragments,   shown   as   two  

343

orthogonal  views.  The  spike  protomers  are  coloured  pink,  blue  and  grey,  and  the  47D11  heavy  

344

and  light  chain  are  coloured  yellow  and  purple,  respectively.  For  clarity,  only  the  Fab  variable  

345

region  is  shown.    

346

  

347

Figure  2:  47D11  binds  specifically  to  the  closed  RBD  and  prevents  their  full  compaction.  

348

A)  Top  view  of  the  47D11  bound  SARS2  spike.  The  spike  protomers  are  coloured  pink,  blue  

349

and  grey,  and  the  47D11  heavy  and  light  chain  are  coloured  yellow  and  purple,  respectively.  

350

Glycans,  and  the  N-­terminal  domain,  are  omitted  for  clarity  and  only  the  Fab  variable  region  

351

is  shown.  The  superposed  structure  of  the  partially  open  apo  SARS2  spike  (PDB  ID:  6ZGG)  

352

is  shown  as  a  silhouette.  B)  Zoomed  in  view  of  the  boxed  region  in  panel  A.  C)  Zoomed  in  

353

view  of  the  SARS2  open  RBD  and  adjacent  NTD.  The  overlaid  47D11  Fab  is  shown  semi-­

354

transparent  and  the  N343  glycan  is  shown  in  ball-­and-­stick  representation  and  coloured  tan.  

355

D)  Top  view  of  the  47D11  bound  SARS2  spike  coloured  as  shown  in  panel  A.  The  superposed  

356

structure  of  the  closed  apo  SARS  spike  (PDB  ID:  5XLR)  is  shown  as  a  silhouette.  E)  Zoomed  

357

in   view   of   the  boxed   region   in   panel   D,   showing  a  putative   salt  bridge   between   the   47D11  

358

variable  light  chain  and  the  RBD  loop.  F)  ELISA-­binding  curves  of  47D11  binding  to  wildtype  

359

and  loop  swapped  spike  ectodomains.    

360

  

361

Figure  3:  The  47D11  epitope  comprises  a  mutationally  constrained  hydrophobic  pocket  

362

which  is  normally  shielded  by  glycan  N343.  A)  Ribbon  diagram  of  the  SARS2-­S  receptor-­

363

binding  domain  (RBD)  in  complex  with  the  47D11  antibody  Fab  fragment.  For  comparison,  

364

residues  1-­84  of  the  RBD  bound  ACE2  (PDB  ID:  6M0J)  are  shown  as  a  silhouette.  B)  Close-­

365

up   view   of   the   47D11   epitope   with   the   hydrophobic   pocket   residues   shown   as   sticks   and  

366

coloured  dark  blue.  The  N343  glycan  is  shown  in  ball-­and-­stick  representation  and  coloured  

367

tan.  For  clarity,  only  the  core  pentasaccharide  is  shown.  C)  Slice  through  the  surface  rendered  

368

47D11  bound  SARS2-­S  RBD.  D)  Equivalent  view  as  shown  in  panel  C  for  the  apo  RBD  (PDB  

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  

  

  

369

ID:6VYB).  E)  Relative  surface  binding  of  47D11,  (F)  ACE2,  (G)  CR3022  and  (H)  an  anti-­FLAG  

370

antibody  to  full-­length  SARS2  spike  epitope  mutants,  determined  by  fluorescence-­activated  

371

cell   sorting.   I)   Antibody-­mediated   neutralization   of   infection   of   luciferase-­encoding   VSV  

372

particles  pseudotyped  with  wild-­type,  V367A  or  V367F  SARS2-­S.  J)  Surface  representation  

373

of  the  47D11  bound  SARS2-­S  RBD  coloured  according  to  mean  mutation  effect  on  expression  

374

(red  indicates  more  constrained)(46).  The  Fab  is  shown  as  a  ribbon  diagram.  K)  As  shown  in  

375

E  for  the  S309  bound  SARS2  RBD.  

376

  

377

Figure  4:  The  47D11  epitope  is  conserved  in  SARS-­like  viruses.  A)  Surface  representation  

378

of   the   47D11   bound   RBD   coloured   according   to   sequence   conservation   across   SARS-­1,  

379

SARS2  and  11  SARS-­like  viruses  (Supplementary  Figure  5).  The  47D11  Fab  variable  chains  

380

are  shown  as  a  ribbon  diagram  and  coloured  grey.  Heavy  chain  residues  W102  and  F103  are  

381

shown  as  sticks.  For  comparison,  residues  1-­84  of  the  RBD  bound  ACE2  (PDB  ID:  6M0J)  are  

382

shown   as   a   silhouette.   B)   ELISA-­binding   curves   of   47D11   to   the   S1B   domain   of   SARS,  

383

SARS2,  WIV16,  HKU3-­3  and  HKU9-­3.  The  average  ±  SD  from  two  independent  experiments  

384

with  technical  duplicates  is  shown.  C)  Aligned  RBD  sequences  of  SARS2,  SARS-­1,  WIV16,  

385

HKU3-­3  and  HKU9-­3.  Key  residues  in  the  47D11  epitope  are  indicated  by  red  arrows.  

386

  

387

  

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  
388

389
390

  

  

Figure  1  

  
  

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  
391

  

  

Figure  2  

392

  

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  
393

  

  

Figure  3  

394

  

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  
395

  

  

Figure  4  

396
397

  

398

Data  availability  

399

Coordinates  for  the  47D11-­bound  SARS-­CoV  and  SARS-­CoV-­2  spike  proteins  are  deposited  

400

in   the   Protein   Data   Bank   under   accession   codes   7AKJ   and   7AKD,   respectively.   The  

401

corresponding  EM  density  maps  have  been  deposited  to  the  Electron  Microscopy  Data  Bank  

402

under   the   accessions   EMD-­11813   and   EMD-­11812.   All   reagents   and   relevant   data   are  

403

available  from  the  authors  upon  request.  

  

  

404

Acknowledgements  

405

This   work   was   supported   by   the  European   Research   Council   under   the   European   Union’s  

406

Horizon2020  Programme  (ERC  Consolidator  Grant  Agreement  724425  -­  BENDER).  J.F.  and  

407

D.L.H.  are  funded  from  the  European  Union’s  Horizon  2020  research  and  innovation  program  

408

under  the  Marie  Skłodowska-­Curie  grant  agreement  (No  792575  and  842333).  J.F.  and  D.L.H.  

409

also   hold   EMBO   non-­stipendiary   long-­term   Fellowships   (ALTF   948-­2017   and   ALTF   1172-­

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  

  

  

410

2018).  Research  reported  in  this  publication  was  supported  by  a  China  Scholarship  Council  

411

grant  to  C.W.  (CSC201708620178).  We  thank  Dr  Mihajlo  Vanevic  for  IT  support.  

412

Author  contributions  

413

  

414

J.F.,  D.L.H.,  C.W.,  W.L.,  F.J.M.K.,  F.F.  and  B.J.B.  conceived,  designed,  and  coordinated  the  

415

study.  J.F.,  D.L.H.,  C.W.,  W.L.,  I.D.,  G.O.,  and  S.H.  conducted  the  experiments.  F.J.M.K,  F.F.  

416

and  B.J.B.  supervised  part  of  the  experiments.  All  authors  contributed  to  the  interpretations  

417

and  conclusions  presented.  J.F.  D.L.H.  and  B.J.B.  wrote  the  manuscript,  J.F.,  D.L.H,  C.W.,  

418

W.L.  F.F.  and  B.J.B  participated  in  editing  the  manuscript.  

419

Competing  interests  

420

A   patent   application   has   been   filed   on   12   March   2020   on   monoclonal   antibodies   targeting  

421

SARS-­CoV-­2  (United  Kingdom  patent  application  no.  2003632.3;;  patent  applicants:  Utrecht  

422

University,  Erasmus   Medical   Center   and   Harbour   BioMed).   I.D.   is  an  employee   of   Thermo  

423

Fisher  Scientific.  The  other  authors  declare  no  competing  interests.    

424

Corresponding  authors  

425

Correspondence   to   Friedrich   Förster   (f.g.forster@uu.nl)   and   Berend-­Jan   Bosch  

426

(b.j.bosch@uu.nl).  

427

References  

428
429

1.  

P.  Zhou  et  al.,  A  pneumonia  outbreak  associated  with  a  new  coronavirus  of  probable  
bat  origin.  Nature.  579,  270–273  (2020).  

430
431

2.  

T.   G.   Ksiazek   et   al.,   A   novel   coronavirus   associated   with   severe   acute   respiratory  
syndrome.  N.  Engl.  J.  Med.  348,  1953–1966  (2003).  

432
433

3.  

Coronaviridae  Study  Group  of  the  International  Committee  on  Taxonomy  of  Viruses,  
(Nature  Publishing  Group,  2020),  vol.  5,  pp.  536–544.  

434
435

4.  

P.  Prabakaran  et  al.,  Potent  human  monoclonal  antibodies  against  SARS  CoV,  Nipah  
and  Hendra  viruses.  Expert  Opin  Biol  Ther.  9,  355–368  (2009).  

436
437

5.  

E.  O.  Saphire,  S.  L.  Schendel,  B.  M.  Gunn,  J.  C.  Milligan,  G.  Alter,  Antibody-­mediated  
protection  against  Ebola  virus.  Nat.  Immunol.  19,  1169–1178  (2018).  

438
439

6.  

A.  Casadevall,  L.-­A.  Pirofski,  The  convalescent  sera  option  for  containing  COVID-­19.  
J.  Clin.  Invest.  130,  1545–1548  (2020).  

440
441

7.  

A.   C.   Cunningham,   H.   P.   Goh,   D.   Koh,   Treatment   of   COVID-­19:   old   tricks   for   new  
challenges.  Crit  Care.  24,  91–2  (2020).  

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  

  

  

442
443

8.  

F.   Li,   Structure,   Function,   and   Evolution   of   Coronavirus   Spike   Proteins.  
http://dx.doi.org/10.1146/annurev-­virology-­110615-­042301.  3,  237–261  (2016).  

444
445
446

9.  

B.-­J.  Bosch,  R.  van  der  Zee,  C.  A.  M.  de  Haan,  P.  J.  M.  Rottier,  The  coronavirus  spike  
protein  is  a  class  I  virus  fusion  protein:  structural  and  functional  characterization  of  the  
fusion  core  complex.  Journal  of  Virology.  77,  8801–8811  (2003).  

447
448
449

10.  

M.  Gui  et  al.,  Cryo-­electron  microscopy  structures  of  the  SARS-­CoV  spike  glycoprotein  
reveal  a  prerequisite  conformational  state  for  receptor  binding.  Cell  Res.  27,  119–129  
(2017).  

450
451

11.  

D.   Wrapp   et   al.,   Cryo-­EM   structure   of   the   2019-­nCoV   spike   in   the   prefusion  
conformation.  Science.  367,  1260–1263  (2020).  

452
453

12.  

A.   C.   Walls   et   al.,   Structure,   Function,   and   Antigenicity   of   the   SARS-­CoV-­2   Spike  
Glycoprotein.  Cell.  181,  281–292.e6  (2020).  

454
455

13.  

J.  Lan  et  al.,  Structure  of  the  SARS-­CoV-­2  spike  receptor-­binding  domain  bound  to  the  
ACE2  receptor.  Nature.  579,  1–6  (2020).  

456
457

14.  

R.  Yan  et  al.,  Structural  basis  for  the  recognition  of  SARS-­CoV-­2  by  full-­length  human  
ACE2.  Science.  367,  1444–1448  (2020).  

458
459

15.  

M.  Hoffmann  et  al.,  SARS-­CoV-­2  Cell  Entry  Depends  on  ACE2  and  TMPRSS2  and  Is  
Blocked  by  a  Clinically  Proven  Protease  Inhibitor.  Cell.  181,  271–280.e8  (2020).  

460
461

16.  

A.  C.  Walls  et  al.,  Tectonic  conformational  changes  of  a  coronavirus  spike  glycoprotein  
promote  membrane  fusion.  Proc.  Natl.  Acad.  Sci.  U.S.A.  114,  11157–11162  (2017).  

462
463

17.  

Y.   Cai   et   al.,   Distinct   conformational   states   of   SARS-­CoV-­2   spike   protein.   Science,  
eabd4251  (2020).  

464
465

18.  

D.  van  Riel,  E.  de  Wit,  Next-­generation  vaccine  platforms  for  COVID-­19.  Nat.  Mater.  
19,  810–812  (2020).  

466
467

19.  

J.  Hansen  et  al.,  Studies  in  humanized  mice  and  convalescent  humans  yield  a  SARS-­
CoV-­2  antibody  cocktail.  Science.  369,  1010–1014  (2020).  

468
469

20.  

P.  J.  M.  Brouwer  et  al.,  Potent  neutralizing  antibodies  from  COVID-­19  patients  define  
multiple  targets  of  vulnerability.  Science.  369,  643–650  (2020).  

470
471

21.  

R.  Shi  et  al.,  A  human  neutralizing  antibody  targets  the  receptor-­binding  site  of  SARS-­
CoV-­2.  Nature.  584,  120–124  (2020).  

472
473

22.  

S.  J.  Zost  et  al.,  Potently  neutralizing  and  protective  human  antibodies  against  SARS-­
CoV-­2.  Nature.  584,  443–449  (2020).  

474
475

23.  

S.  J.  Zost  et  al.,  Rapid  isolation  and  profiling  of  a  diverse  panel  of  human  monoclonal  
antibodies  targeting  the  SARS-­CoV-­2  spike  protein.  Nat.  Med.  26,  1422–1427  (2020).  

476
477

24.  

D.  F.  Robbiani  et  al.,  Convergent  antibody  responses  to  SARS-­CoV-­2  in  convalescent  
individuals.  Nature.  584,  437–442  (2020).  

478
479

25.  

T.   F.   Rogers   et   al.,   Isolation   of   potent   SARS-­CoV-­2   neutralizing   antibodies   and  
protection  from  disease  in  a  small  animal  model.  Science.  369,  956–963  (2020).  

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  

  

  

480
481
482

26.  

Y.   Cao   et  al.,   Potent   neutralizing   antibodies   against  SARS-­CoV-­2   identified  by  high-­
throughput   single-­cell   sequencing   of   convalescent   patients'   B   cells.   Cell   (2020),  
doi:10.1016/j.cell.2020.05.025.  

483
484

27.  

M.  Yuan  et  al.,  A  highly  conserved  cryptic  epitope  in  the  receptor  binding  domains  of  
SARS-­CoV-­2  and  SARS-­CoV.  Science.  368,  630–633  (2020).  

485
486

28.  

W.  Li  et  al.,  Potent  neutralization  of  SARS-­CoV-­2  in  vitro  and  in  an  animal  model  by  a  
human  monoclonal  antibody.  bioRxiv.  525,  129  (2020).  

487
488

29.  

A.  Z.  Wec  et  al.,  Broad  neutralization  of  SARS-­related  viruses  by  human  monoclonal  
antibodies.  Science.  369,  731–736  (2020).  

489
490

30.  

B.  Ju  et  al.,  Human  neutralizing  antibodies  elicited  by  SARS-­CoV-­2  infection.  Nature.  
584,  115–119  (2020).  

491
492

31.  

Y.  Wu  et  al.,  A  noncompeting  pair  of  human  neutralizing  antibodies  block  COVID-­19  
virus  binding  to  its  receptor  ACE2.  Science.  368,  1274–1278  (2020).  

493
494
495

32.  

E.  Seydoux  et  al.,  Analysis  of  a  SARS-­CoV-­2-­Infected  Individual  Reveals  Development  
of   Potent   Neutralizing   Antibodies   with   Limited   Somatic   Mutation.   Immunity.   53,   98–
105.e5  (2020).  

496
497
498

33.  

C.   O.   Barnes   et   al.,   Structures   of   Human   Antibodies   Bound   to   SARS-­CoV-­2   Spike  
Reveal   Common   Epitopes   and   Recurrent   Features   of   Antibodies.   Cell.   182,   828–
842.e16  (2020).  

499
500

34.  

H.  Lv  et  al.,  Cross-­reactive  Antibody  Response  between  SARS-­CoV-­2  and  SARS-­CoV  
Infections.  Cell  Rep.  31,  107725  (2020).  

501
502

35.  

D.   Pinto   et  al.,   Cross-­neutralization   of   SARS-­CoV-­2  by  a  human   monoclonal  SARS-­
CoV  antibody.  Nature.  583,  1–10  (2020).  

503
504

36.  

D.  Zhou  et  al.,  Structural  basis  for  the  neutralization  of  SARS-­CoV-­2  by  an  antibody  
from  a  convalescent  patient.  Nat.  Struct.  Mol.  Biol.  20,  773–9  (2020).  

505
506

37.  

H.  Liu  et  al.,  Cross-­neutralization  of  a  SARS-­CoV-­2  antibody  to  a  functionally  conserved  
site  is  mediated  by  avidity.  bioRxiv  (2020),  doi:10.1101/2020.08.02.233536.  

507
508

38.  

Z.   Lv   et   al.,   Structural   basis   for   neutralization   of   SARS-­CoV-­2   and   SARS-­CoV   by   a  
potent  therapeutic  antibody.  Science.  369,  1505–1509  (2020).  

509
510

39.  

X.  Chi  et  al.,  A  neutralizing  human  antibody  binds  to  the  N-­terminal  domain  of  the  Spike  
protein  of  SARS-­CoV-­2.  Science.  369,  650–655  (2020).  

511
512

40.  

B.   R.   West   et   al.,   Structural   Basis   of   Pan-­Ebolavirus   Neutralization   by   a   Human  
Antibody  against  a  Conserved,  yet  Cryptic  Epitope.  MBio.  9,  365  (2018).  

513
514

41.            C.   Wang   et   al.,   A   human   monoclonal   antibody   blocking   SARS-­CoV-­2   infection.   Nat  
Commun.  11,  2251–6  (2020).  

515
516

42.           B.  Haagmans  et  al.,  SARS-­CoV-­2  neutralizing  human  antibodies  protect  against  lower  
respiratory  tract  disease  in  a  hamster  model.  bioRxiv.  doi:10.1101/2020.08.24.264630  

517
518

43.  

  
  

Y.  Yuan  et  al.,  Cryo-­EM  structures  of  MERS-­CoV  and  SARS-­CoV  spike  glycoproteins  
reveal  the  dynamic  receptor  binding  domains.  Nat  Commun.  8,  15092–9  (2017).  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  

  

  

519
520

44.  

C.  Toelzer  et  al.,  Free  fatty  acid  binding  pocket  in  the  locked  structure  of  SARS-­CoV-­2  
spike  protein.  Science,  eabd3255  (2020).  

521
522

45.  

T.  Koyama,  D.  Platt,  L.  Parida,  Variant  analysis  of  SARS-­CoV-­2  genomes.  Bull.  World  
Health  Organ.  98,  495–504  (2020).  

523
524
525

46.  

T.  N.  Starr  et  al.,  Deep  Mutational  Scanning  of  SARS-­CoV-­2  Receptor  Binding  Domain  
Reveals   Constraints   on   Folding   and   ACE2   Binding.   Cell   (2020),  
doi:10.1016/j.cell.2020.08.012.  

526
527

47.  

D.   Wrapp   et   al.,   Structural   Basis   for   Potent   Neutralization   of   Betacoronaviruses   by  
Single-­Domain  Camelid  Antibodies.  Cell.  181,  1004–1015.e15  (2020).  

528
529
530

48.  

C.  O.  Barnes  et  al.,  Structural  classification  of  neutralizing  antibodies  against  the  SARS-­
CoV-­2   spike   receptor-­binding   domain   suggests   vaccine   and   therapeutic   strategies.  
bioRxiv  (2020),  doi:10.1101/2020.08.30.273920  

531
532

49.  

M.   A.   Tortorici   et   al.,   Ultrapotent   human   antibodies   protect   against   SARS-­CoV-­2  
challenge  via  multiple  mechanisms.  Science.  4,  eabe3354  (2020).  

533
534

50.  

A.   H.   M.   Wong   et   al.,   Receptor-­binding   loops   in   alphacoronavirus   adaptation   and  
evolution.  Nat  Commun.  8,  1735–10  (2017).  

535
536
537

51.  

M.  Schorb,  I.  Haberbosch,  W.  J.  H.  Hagen,  Y.  Schwab,  D.  N.  Mastronarde,  Software  
tools   for   automated   transmission   electron   microscopy.   Nat.   Methods.   16,   471–477  
(2019).  

538
539

52.  

J.   Zivanov,   T.   Nakane,   S.   H.   W.   Scheres,   A   Bayesian   approach   to   beam-­induced  
motion  correction  in  cryo-­EM  single-­particle  analysis.  IUCrJ.  6,  5–17  (2019).  

540
541

53.  

S.   Q.   Zheng   et   al.,   MotionCor2:   anisotropic   correction   of   beam-­induced   motion   for  
improved  cryo-­electron  microscopy.  Nat.  Methods.  14,  331–332  (2017).  

542
543

54.  

A.  Rohou,  N.  Grigorieff,  CTFFIND4:  Fast  and  accurate  defocus  estimation  from  electron  
micrographs.  Journal  of  Structural  Biology.  192,  216–221  (2015).  

544
545

55.  

E.  F.  Pettersen  et  al.,  UCSF  Chimera-­-­a  visualization  system  for  exploratory  research  
and  analysis.  J  Comput  Chem.  25,  1605–1612  (2004).  

546
547

56.  

P.   Emsley,   K.   Cowtan,   Coot:   model-­building   tools   for   molecular   graphics.   Acta  
Crystallogr.  D  Biol.  Crystallogr.  60,  2126–2132  (2004).  

548
549

57.  

A.   C.   Walls  et  al.,   Unexpected   Receptor   Functional   Mimicry   Elucidates   Activation  of  
Coronavirus  Fusion.  Cell.  176,  1026–1039.e15  (2019).  

550
551

58.  

Q.  Wang  et  al.,  Neutralization  mechanism  of  human  monoclonal  antibodies  against  Rift  
Valley  fever  virus.  Nat  Microbiol.  4,  1231–1241  (2019).  

552
553
554

59.  

A.   Cassotta   et   al.,   A   single   T   cell   epitope   drives   the   neutralizing   anti-­drug   antibody  
response   to   natalizumab   in   multiple   sclerosis   patients.   Nat.   Med.   25,   1402–1407  
(2019).  

555
556

60.  

G.  Bunkóczi,  R.  J.  Read,  Improvement  of  molecular-­replacement  models  with  Sculptor.  
Acta  Crystallogr.  D  Biol.  Crystallogr.  67,  303–312  (2011).  

  
  

  

  

bioRxiv preprint doi: https://doi.org/10.1101/2020.09.30.318261; this version posted October 2, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC-ND 4.0 International license.

  
  

  

  

557
558
559

61.  

J.   J.   Headd   et   al.,   Use   of   knowledge-­based   restraints   in   phenix.refineto   improve  
macromolecular  refinement  at  low  resolution.  Acta  Crystallogr.  D  Biol.  Crystallogr.  68,  
381–390  (2012).  

560
561

62.  

T.   I.   Croll,   ISOLDE:   a   physically   realistic   environment   for   model   building   into   low-­
resolution  electron-­density  maps.  Acta  Crystallogr  D  Struct  Biol.  74,  519–530  (2018).  

562
563

63.  

V.   B.   Chen   et   al.,   MolProbity:   all-­atom   structure   validation   for   macromolecular  
crystallography.  Acta  Crystallogr.  D  Biol.  Crystallogr.  66,  12–21  (2010).  

564
565

64.  

J.   Agirre   et   al.,   Privateer:   software   for   the   conformational   validation   of   carbohydrate  
structures.  Nat.  Struct.  Mol.  Biol.  22,  833–834  (2015).  

566
567

65.  

J.  Agirre,  G.  Davies,  K.  Wilson,  K.  Cowtan,  Carbohydrate  anomalies  in  the  PDB.  Nat.  
Chem.  Biol.  11,  303–303  (2015).  

568
569

66.  

E.  Krissinel,  K.  Henrick,  Inference  of  macromolecular  assemblies  from  crystalline  state.  
J.  Mol.  Biol.  372,  774–797  (2007).  

570
571

67.  

W.   Tian,   C.   Chen,   X.   Lei,   J.   Zhao,   J.   Liang,   CASTp   3.0:   computed   atlas   of   surface  
topography  of  proteins.  Nucleic  Acids  Res.  46,  W363–W367  (2018).  

572
573

68.  

T.  D.  Goddard  et  al.,  UCSF  ChimeraX:  Meeting  modern  challenges  in  visualization  and  
analysis.  Protein  Sci.  27,  14–25  (2018).  

574

  

  
  

  

  

